Galderma today announced that it will present new data from the ARCADIA and OLYMPIA clinical trial programs investigating ...

Prurigo nodularis (PN) is a chronic (long-term) skin condition that causes intense itching and firm bumps on the outer layer ...

Dermatology specialist Galderma has FDA approval for prurigo nodularis treatment Nemluvio, one of two new drugs that it thinks will deliver blockbuster sales. The US regulator cleared the IL-31 ...

Prurigo nodularis is a skin condition that causes severe itchiness. Eczema can be an initial trigger for prurigo nodularis, and a person can have both conditions at the same time. Both prurigo ...

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Shares of Celldex Therapeutics CLDX lost 12.1% on Wednesday due to unsatisfactory 52-week safety data from a mid-stage study ...

EADV: New data reinforce Sanofi’s innovative approach and leadership across immune-mediated skin diseases: Paris Thursday, September 26, 2024, 10:00 Hrs [IST] Sanofi will presen ...

Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the EADV 2024 Congress ...

New 56-week data from an interim analysis of the phase III ARCADIA long-term extension study will be presented, with nemolizumab demonstrating a ...

Medically reviewed by William Truswell, MDMedically reviewed by William Truswell, MD Prurigo nodularis (PN) is a chronic (long-term) skin condition that causes intense itching and firm bumps on ...